Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?-Reference-Cited by-同舟云学术

Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?

Published:2009-10-01 Issue:19 Volume:115 Page:4477-4487
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Denham James W.,Steigler Allison,Wilcox Chantelle,Lamb David S.,Joseph David,Atkinson Chris,Tai Keen-Hun,Spry Nigel A.,Gleeson Paul S.,D'Este Catherine

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.24484/fullpdf

Reference31 articles.

1. Biochemical (prostate specific antigen) recurrence a probability following radical prostatectomy for clinically localized prostate cancer;Han;J Urol,2003

2. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results;Roehl;J Urol,2004

3. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy;Lerner;J Urol,1996

4. Outcome based staging for clinically localized adenocarcinoma of the prostate;D'Amico;J Urol,1997

5. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era;Kupelian;Int J Radiat Oncol Biol Phys,2002

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review;European Urology;2019-06

2. Prognostic factors in prostate cancer patients treated by radical external beam radiotherapy;Panminerva Medica;2017-06

3. Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease;European Urology;2017-03

4. Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial;Radiotherapy and Oncology;2016-10

5. Does prostate-specific antigen nadir predict longer-term outcomes of prostate cancer after neoadjuvant and adjuvant androgen deprivation therapy in conjunction with brachytherapy?;Brachytherapy;2015-05